Acute kidney injury in visceral leishmaniasis: a cohort of 10 patients admitted to a specialized intensive care unit in northeast of Brazil

Elizabeth F. Daher¹*, Aline Menezes Sampaio¹, Lorena Vasconcelos M. Martiniano¹, Ana Patrícia Freitas Vieira¹, Geraldo B. Silva Junior¹,²

¹Department of Internal Medicine, School of Medicine, Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
²School of Medicine, Health Sciences Center, University of Fortaleza, Fortaleza, Ceará, Brazil

1. Introduction

Visceral leishmaniasis (VL) is a public health problem in Brazil and other developing countries. The disease is transmitted by the vector Lutzomyia longipalpis and is caused by several species of Leishmania. It is a zoonotic disease typically found in tropical areas, which is now found predominantly in urban and peri-urban areas, affecting the cities of medium and large size in Brazil[1-2].

The number of VL confirmed cases from 2004 to 2010 was 3467 in Ceará state, Northeast Brazil[3]. VL can develop serious complications such as acute kidney injury (AKI) that may need intensive care unit (ICU). This disease was responsible for 4.1% of AKI in ICU admissions, and the number of deaths

*Corresponding author: Elizabeth De Francesco Daher. Rua Vicente Linhares, 1198, Fortaleza, CE, Brazil – CEP: 60135-270. Tel.: +55 (85) 3224-9725 Fax: +55 (85) 3261-3777. E-mail: ef.daher@uol.com.br, geraldobezerrajr@yahoo.com.br

Foundation Project: Supported by the Brazilian Research Council (Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq, Brazil, protocol 475040/2011-2).
was 174 (5%) in a cohort of VL patients in our region[4]. Several authors have described renal pathological changes in VL[5-9]. The main pathophysiological mechanism responsible for renal impairment in VL probably includes the deposition of immune complexes. The most frequent pathologies found are proliferative glomerulonephritis and interstitial nephritis[10]. The development of AKI is an important clinical complication in patients with VL, which appears to increase the mortality rate in this group of patients[10].

The aim of this study is to describe clinical manifestations, laboratory tests, comorbidities and outcome of patients with visceral leishmaniasis and AKI admitted to a reference intensive care unit in Northeast Brazil.

2. Materials and methods

2.1. Study population

This is a case study with ten patients with confirmed diagnosis of VL admitted to the ICU of São José Infectious Diseases Hospital in Fortaleza city, Northeast of Brazil, between January 2004 and December 2009, with renal injury. All patients had clinical and epidemiological data suggestive of VL. Confirmed infection was defined by mielogram and positive serologic K-39. They were selected from a group of 253 patients admitted to the ICU with AKI in this period.

2.2. Clinical and laboratory parameters evaluated

The clinical parameters were age, sex, onset of symptoms to admission, length of hospital stay, admission mean blood pressure, clinical symptoms, causes of hospitalization, medications in use, comorbidities, co-infections, cause of death, dialysis requirement, type of dialysis, number of sessions and days after AKI diagnosis to start dialysis.

Laboratory tests were serum urea and creatinine, total blood count, aspartate amino transaminase (AST), alanine amino transaminase (ALT), maximal serum urea (SU_max), serum urea at admission (SU_adm) and discharge (SU_dis), maximal serum creatinine (SCR_max), serum creatinine at admission (SCR_adm) and discharge (SCR_dis), prothrombin time, total bilirubin, indirect bilirubin, direct bilirubin, serum sodium and potassium, arterial pH, pCO₂, pO₂, HCO₃, and IFO₂.

2.3. Definitions

Acute kidney injury (AKI) was defined according to the RIFLE classification (Risk, Injury, Failure, Loss, and End-stage kidney disease[12]). Hypotension was defined as mean arterial blood pressure (MAP) <60 mmHg, and therapy with vasoactive medication was initiated when the MAP remained <60 mmHg despite fluid administration. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded at admission. Lung manifestation was considered if patients present with dyspnea, pulmonary crackles, hemoptysis, or PO₂ < 60 mmHg in arterial blood gas. Oliguria was considered to be present when the urinary volume was < 400 mL/day after adequate fluid replacement. Dialysis was indicated for those patients who remained oliguric after effective hydration, in those cases where uremia was associated with hemorrhagic or severe respiratory failure, in severe cases or refractory metabolic acidosis and severe or refractory hyperkalemia.

2.4. Ethics

The protocol of this study was approved by the Ethical Committee of the Walter Cantidio University Hospital and São José Infectious Diseases Hospital.

Table 1

Clinical characteristics at admission of 10 cases with visceral leishmaniasis and acute kidney injury.

| Case Number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-------------|---|---|---|---|---|---|---|---|---|----|
| Age (Years) | 17 | 49 | 51 | 47 | 34 | 34 | 73 | 36 | 35 | 44 |
| Gender | M | M | M | M | M | F | M | M | M |
| Onset of symptoms to admission (day) | 90 | 365 | 120 | 60 | 90 | 20 | 40 | 30 | 45 | 60 |
| Length of hospital stay (day) | 48 | 303 | 38 | 24 | 10 | 33 | 7 | 17 | 85 | 47 |
| Admission mean blood pressure | | | | | | | | | | |
| SBP (mmHg) | 115 | 173 | 120 | 101 | 104 | 127 | 150 | 146 | 138 | 88 |
| DBP (mmHg) | 78 | 94 | 70 | 49 | 74 | 77 | 50 | 90 | 87 | 51 |
| Other Diseases | | | | | | | | | | |
| AIDS | N | Y | N | N | Y | N | Y | N | N |
| TB | N | N | N | N | Y | N | Y | N | N |
| Leprosy | N | N | N | N | N | Y | N | N |
| Use of mechanical ventilation | N | Y | N | Y | N | Y | Y | Y | N |
| Oliguria | N | N | Y | Y | Y | Y | N | N | Y |
| Death | N | N | N | Y | Y | Y | N | Y |

M: male; F: female; SBP: Systolic Blood Pressure; DBP: Diastolic blood pressure; TB: Tuberculosis; Y: yes; N: No.
3. Results

This study found 10 (4%) patients with VL in a group of 253 patients admitted to the ICU with AKI in 6 years. The patients mean age was (42.0±14.7) years, with 90% males. The majority (60%) of them were from rural areas. The time between the onset of symptoms and hospital admission ranged from 20 to 365 d (mean 92±100.7 d). The duration of hospital stay ranged from 7 to 303 days (mean 61.2±87.9 d).

The main signs and symptoms presented at admission were weight loss (100%), fever (100%), splenomegaly (70%), jaundice (60%), anorexia (60%), asthenia, bleeding and vomits (40%). Pancytopenia occurred in 50% of cases. The mean systolic blood pressure at admission was 126.2±25.9 mmHg and diastolic blood pressure was 72±16.8 mmHg. The main co-infections were: AIDS (40%), tuberculosis (20%) and leprosy (10%). The main comorbidities were diabetes mellitus (20%), systemic arterial hypertension (10%) and respiratory insufficiency (10%). The medications in use were hydration (100%), loop diuretic (50%), vasopressor (40%), angiotensin converting enzyme inhibitors (20%) and sulfa (10%).

The main laboratory tests in the first 24 hours after AKI diagnosis were Ht 25.9±4.7% (16.4%-32.7%), Hb 8.6±1.6 g/dL (5.6-10.8 g/dL), white blood count 3 820±4160/mm$^3$ (700-14 400/mm$^3$), platelets count 89920±48.233.8/mm$^3$ (16 000-156 000/mm$^3$), AST 300.3±364.6 IU/L (13.8-1220 IU/L), ALT 233.1±413.9 IU/L (9-1350 IU/L), total bilirubin 4.9±5.2 IU/L (0.73-13.2 IU/L), direct bilirubin 3.7±4.6 IU/L (0.5-12 IU/L), serum urea 105.5±27.6 mg/dL (75.1-165 mg/dL), serum creatinine 2.1±1.6 g/dL (0.6-10.8 g/dL), white blood count 280±4160/mm$^3$ (700-14 400/mm$^3$), platelets count 89920±48.233.8/mm$^3$ (16 000-156 000/mm$^3$), AST 300.3±364.6 IU/L (13.8-1220 IU/L), ALT 233.1±413.9 IU/L (9-1350 IU/L), total bilirubin 4.9±5.2 IU/L (0.73-13.2 IU/L), direct bilirubin 3.7±4.6 IU/L (0.5-12 IU/L), prothrombin time 28.6±12.2 seconds (14.8-46 seconds), serum urea 105.5±27.6 mg/dL (75.1-165 mg/dL), serum creatinine 2.1±1.6 g/dL (0.6-10.8 g/dL), K$^+$ 4.3±0.9 mEq/L (3.2-6.6 mEq/L), Na$^+$ 131±7.2 mEq/L (121-144 mEq/L), FiO$_2$ (%): Inspired fraction of O$_2$.

### Table 2

| Case number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-------------|---|---|---|---|---|---|---|---|---|----|
| Laborotary findings | | | | | | | | | | |
| Cr (mg/dL) | 2.1 | 1.6 | 5 | 3.3 | 1.8 | 3.6 | 2 | 3.5 | 2 | 1.8 |
| Ur (mg/dL) | 111 | 75.1 | 136 | 165 | 86 | 104 | 88 | 115 | 86 | 89 |
| TGO (IU/L) | 100 | 13.8 | 422 | 1220 | 440 | 26 | 107 | 221 | 47 | 406 |
| TGP (IU/L) | 100 | 11.9 | 167 | 1230 | 450 | 9 | 35 | 136 | 18 | 55 |
| TAP (s) | -- | -- | -- | 31 | 29.3 | -- | 22.7 | -- | 46 | 46 |
| Na$^+$ (mEq/L) | 3.5 | 3.8 | 3.7 | 4.8 | 6.6 | 6.6 | 3.2 | 4.4 | 4.8 | 4.1 |
| BT (mg/dL) | 1.1 | 1.6 | 3.8 | 0.73 | 13.2 | 0.8 | 13.2 | 10.28 | 13.7 | 3.24 |
| BD (mg/dL) | 1 | 0.5 | 1.1 | 0.66 | 12 | 0.5 | 11.61 | 5.88 | 1.19 | 3.19 |
| BI (mg/dL) | 0.1 | 1.1 | 2.7 | 0.07 | 1.2 | 1.2 | 1.3 | 1.59 | 4.4 | 0.18 |
| Ht (%) | 22.8 | 30.7 | 23.9 | 16.4 | 32.7 | 26.5 | 23.9 | 29.5 | 23.8 | 29.1 |
| Hb (g/dL) | 7.6 | 10.5 | 8 | 5.6 | 10.8 | 8.6 | 7.6 | 10.6 | 7.9 | 9.7 |
| White blood count (/mm$^3$) | 1 300 | 4800 | 700 | 2 300 | 6 800 | 2 900 | 2 400 | 1 200 | 1 400 | 14 400 |
| Platelets (/mm$^3$) | 114 000 | 90 000 | 37 000 | 98 000 | 28 000 | 16 000 | 156 000 | 140 000 | 94 200 | 126 000 |
| pH | 7.44 | 7.38 | 7.37 | 7.4 | 7.4 | 7.33 | 7.33 | 7.28 | 7.33 | 7.29 |
| pO$_2$ (mmHg) | 98 | -- | -- | 59.8 | 137.9 | 114 | 128 | 108 | 138.2 | 75.9 |
| pCO$_2$ (mmHg) | 24.4 | 47.2 | 32.3 | 28 | 24 | 30 | 39 | 37.5 | 19.5 | 24 |
| HCO$_3$ (mEq/L) | 16.2 | 27.2 | 18.9 | 12.3 | 15.6 | 15 | 17 | 17.6 | 10.1 | 11.4 |
| FiO$_2$ (%) | 21% | -- | 21% | 100% | 50% | 50% | 60% | 40% | 28% | 50% |

Hb: Hemoglobin; Ht: Hematocrit; TB: Total bilirubin; DB: Direct bilirubin; IB: Indirect bilirubin; FiO$_2$: Inspired fraction of O$_2$.

### Table 3

| Case number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-------------|---|---|---|---|---|---|---|---|---|----|
| SU adm (mg/dL) | 33 | 29 | 97 | 40 | 30 | 104 | 88 | 115 | 63 | 16 |
| SU max (mg/dL) | 118 | 78 | 180 | 165 | 86 | 137 | 104 | 145 | 95 | 100 |
| SU dis (mg/dL) | 27 | 75 | 63 | -- | 86 | 118 | 73 | 89.7 | 41 | 100 |
| SCr adm (mg/dL) | 0.6 | 0.7 | 3.1 | 1 | 1 | 3.6 | 2 | 3.5 | 1.4 | 0.57 |
| SCr max (mg/dL) | 3.2 | 2.58 | 7.4 | 3.3 | 1.8 | 4.3 | 2.4 | 5.4 | 2.32 | 2.04 |
| SCr dis (mg/dL) | 1.2 | 1.8 | 3.6 | 1.2 | 1.8 | 1.5 | 2.2 | 0.8 | 0.9 | 2.04 |
| Days after diagnosis of AKI | -- | -- | 0 | 2 | 1 | -- | -- | -- | 1 | 2 |
| Number of dialysis sessions | -- | -- | 21 | 4 | 1 | -- | -- | -- | 3 | 7 |

SU: serum urea; SCr: serum creatinine; Adm: admission; Max: maximum; Dis: discharge.
4. Discussion

This is the first study to investigate AKI in patients with VL admitted in a specialized intensive care unit. Human VL is an endemic parasitic infection in Brazil that has reemerged, especially in peri-urban areas. Renal involvement is considered rare, presenting as hematuria, proteinuria, or renal function impairment[5]. Prospective and cross-sectional studies showed AKI (considered as the levels of serum creatinine above 1.3 mg/dL) in 11% to 33.9% of patients with confirmed VL[10,13,14].

AKI was more frequent in male patients in the present study. This is in accordance with previous study[15]. The analysis of signs and symptoms showed that high frequency of jaundice, weight loss, anorexia, splenomegaly, hepatomegaly and fever, which are commons signs and symptoms in VL[16-20].

This study found that 4 of the 10 patients admitted in the ICU had HIV co-infection. Two of these were had pulmonary tuberculosis. The association between VL and HIV is common and it may have increased the severity of the patients’ clinical condition and the patient become more prone to diseases such as tuberculosis[21]. The diagnosis of VL in patients with HIV infection is difficult, because the occurrence of hepatosplenicomegaly, fever, and skin lesions, which are the main manifestations of VL and this manifestation can be seen in many opportunist infections as histoplasmosis, miliar tuberculosis, and other infections that are common in our region[21-23]. Thus, the difficulty in giving a diagnosis delays treatment for VL. This can increase the damage caused by renal disease. The AKI is a frequent complication that occurs in 10 to 30% of patients with AIDS[24-26]. Common causes of AKI in these patients include use of antiretroviral drugs, volume depletion and sepsis[27].

One patient had also leprosy associated with VL and AKI. Leprosy can cause different types of renal abnormalities. Glomeruli injury has been described in histology findings in leprosy patients, progressive mesangial glomerulonephritis being the most common lesion[28-31]. Many other kinds of glomerulonephritis have also been described[30,32-34]. The incidence of glomerulonephritis has been reported to range from 6% to 50% in leprosy patients[41]. Amyloidosis, the incidence of which ranges from 2% to 55%, is attributed to chronic granulomatous reactions caused by *Mycobacterium leprae*[42]; and it is manifested mainly by significant proteinuria[44]. It may progress to chronic renal failure, which is one of the causes of death in leprosy[43,44]. This makes call attention since the presence of several diseases that cause kidney damage associated to AKI has a poor prognosis and is a risk factor for death[4,5]. Half of the patients studied did not have co-infections. Sixty percent of these died. This poor prognosis should be avoided. This result also leads to concern with patients apparently not so serious, who are already without co-morbidities. Therefore special attention is required with this type of patient admitted to the ICU, especially in ICU hospital of infectious diseases.

In the present study, high mortality rate (60%) was observed. Oliveira et al performed a study with patients not hospitalized in ICU with VL and found a mortality rate of AKI patients 30.2% versus 4.7% in non-AKI[11]. The high value of 60% was due to the severity of the patients in ICU. They had VL, AKI and several comorbidities. In ICU study performed by our group, the mortality rate was 66.6%, and the main cause of death was septic shock (88%)[4]. These findings are similar to those in the present study. Schrier et al. showed that sepsis associated with AKI was responsible to 70% of mortality in hospitalized patients as compared with to 45% mortality among patients with AKI alone[45]. Four patients who died were classified RIFLE-F and just one were RIFLE-I. This evidences that RIFLE-F patients had a higher mortality, which is in accordance to literature. Oliguria was observed in 66% of cases, and it was associated with an even higher mortality (83%).

RIFLE-F patients were younger and had lower blood pressure, longer time between onset of symptoms and hospital admission. Half of them had metabolic acidosis. The mechanical ventilation was used to help in reversal of respiratory insufficiency. This information is confirmed by Daher et al[4]. Their findings support the view that oliguria, metabolic acidosis, sepsis, hypovolaemia, use of vasopressors, mechanical ventilation were factors associated with death[4,46].

In conclusion, AKI is an important complication in LV. The progression of the disease and their complications can achieve high level of severity, even in the absence of comorbidities or co-infections. The high mortality in this group alerts to the importance of early diagnosis and adequate management of these patients. Moreover, it is necessary that patients admitted to the ICU with VL have a detailed investigation to diagnose possible associated diseases. This may allow proper treatment and achieve a better prognosis.
Conflict of interest statement

We declare that we have no conflict of interest.

Comments

Background

Visceral leishmaniasis (VL) is a public health problem in Brazil and other developing countries. Visceral Leishmaniasis (VL) can cause serious complications such as acute kidney injury (AKI) that may need intensive care unit (ICU). The aim of this study is to describe co-infections, clinical manifestations, comorbidities and outcome of patients with visceral leishmaniasis and AKI.

Research frontiers

This study found 10 patients with VL in a group of 253 patients admitted to the ICU with AKI. The main co-infections were: AIDS, tuberculosis and leprosy.

Related reports

Oliveira et al. performed a study with patients not hospitalized in ICU with VL and found a mortality rate of AKI patients 30.2% versus 4.7% in non-AKI. The high value of 60% was due to the severity of the patients in ICU. They had VL, AKI and several comorbidities. In ICU study performed by our group, the mortality rate was 66.6%, and the main cause of death was septic shock (88%). These findings are similar to those in the present study. This evidences that RIFLE-F patients had a higher mortality, which is in accordance to literature. This information is confirmed by Daher et al. Their findings support the view that oliguria, metabolic acidosis, sepsis, hypovolaemia, use of vasopressors, mechanical ventilation were factors associated with death. In conclusion, AKI is an important complication in VL.

Innovations & breakthroughs

AKI is an important complication in VL. This study found 10 (4%) patients with VL in a group of 253 patients admitted to the ICU with AKI. The main co-infections were: AIDS (40%), tuberculosis (20%) and leprosy (10%). The main comorbidities were diabetes mellitus (20%), systemic arterial hypertension (10%) and respiratory insufficiency (10%).

Applications

The progression of the disease and their complications can achieve high level of severity, even in the absence of comorbidities or co-infections. The high mortality in this group alerts to the importance of early diagnosis and adequate management of these patients. Moreover, it is necessary that patients admitted to the ICU with VL have a detailed investigation to diagnose possible associated diseases. This may allow proper treatment and achieve a better prognosis.

Peer review

This is a good cohort study in which the authors found how AKI was important with VL infection as well as other hiding important diseases, AIDS, tuberculosis and leprosy as co-infection. And also they addressed that patients admitted to the ICU with VL should be done a detailed investigation to diagnose possible associated diseases.

References

[1] Brazil. Ministry of Health. Surveillance Secretariat of Health. Severe Visceral Leishmaniasis: Standards and Conduct. Brasilia, DF, 2006. (Series A. Technical Standards and Manuals).
[2] Arias JR. The Reemergence of Visceral Leishmaniasis in Brazil. Emerg Infect Dis 1996; 2: 145–146.
[3] Ministry of Health – SVS – Disease Surveillance System and Population-Based IBGE.
[4] Daher EF, Marques CN, Lima RSA, Silva Junior GB, Barbosa AS, Barbosa ES, et al. Acute kidney injury in infectious disease intensive care unit-assessment of prognostic factors. Swiss Med Wkly 2008; 138: 128–133.
[5] Efstratiadis G, Boura E, Giamalis P. Renal involvement in a patient with visceral leishmaniasis. Nephrol Dial Transplant 2006; 21(S1): 235–236.
[6] Andrade ZA; Yabuki K. The Nephropathy of Kala-azar. Rev Inst Med Trop São Paulo 1972; 14: 51.
[7] Brito HS, Amato Neto V, Duarte IS, Penna DO. Glomerular involvement in human kala-azar. a light immuno-fluorescent and electron microscopic study based on kidney biopsies. Am J Trop Med Hyg 1975; 24: 9–18.
[8] Caravaca F; Munoz A; Pizarro JL. Acute renal failure in visceral leishmaniasis. Am J Nephrol 1991; 11: 350–352.
[9] Prasad LSN; Sen S; Ganguly SK.. Renal involvement in Kala-azar. Indian J Med 1992; 95: 43–46.
[10] Salgado Filho N, Ferreira TMAF, Costa JML. Involvement of the renal function in patients with visceral leishmaniasis (Kala-azar). Rev Soc Bras Med Trop 2003; 36: 217–221.
[11] Oliveira MJG, Silva Junior GB, Abreu KLS, Rocha NA, Garcia AVV, Franco LFLG, et al. Risk factors for acute kidney injury in visceral leishmaniasis (Kala-azar). Am J Trop Med Hyg 2010; 82:449–453.
[12] Venkataraman R, Kellum JA. Defining acute renal failure: The RIFLE criteria. J Intens Care Med 2007; 22: 187.
Lima Verde EM. Evaluation of renal function in human visceral leishmaniasis (Kala–azar): a prospective study of 50 patients from Brazil. J Nephrol 2007; 20: 430–436.

Daher EF, Evangelista LF, Silva Junior GB, Lima RSA, Aragao EB, Arruda GAJC, et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (Kala–azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis 2008; 12:329–332.

Pisani R, Wille KM, Tolwani AJ. The epidemiology of severe acute kidney injury. From BEST to PICARD, in Acute Kidney Injury: New Concepts. Nephron Clin Pract 2008; 109: 188–191.

Person D; Sousa AQ. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996; 22: 1–13.

Patorino AC, Jacob CMA, Oselja GW, Carneiro–Sampaio MMS. Visceral leishmaniasis: Clin Lab Aspects J Ped 2002; 78: 120–127.

Pedrosa CM; Rocha EMM. Clinical and epidemiological aspects of visceral leishmaniasis in children under 15 years coming from Alagoas, Brazil. Rev Soc Bras Med Trop 1994; 37: 300–304.

Xavier–Gomes LM, Costa WB, Prado PPF, Oliveira–Campos M, Leite MT. Clinical and epidemiological characteristics of visceral leishmaniasis in children hospitalized at a reference university hospital in the North of Minas Gerais, Brazil. Rev Bras Epidemiol 2009; 12: 1–6.

Albuquerque PLMM, Silva Junior GB, Freire CCP, Oliveira SBC, Almeida DM, Silva HF, et al. Urbanization of visceral leishmaniasis (Kala–azar) in Fortaleza, Ceara, Brazil. Rev Panam Salud Publica 2009; 26: 330–333.

Daher EF, Fonseca PP, Gerhard ES, Silva Leitão TMJ, Silva Júnior GB. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol 2009; 95: 652–655.

Gallardo JA, Pineda JA, Macias J, Torrontera R, Lissen E. Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in patients with HIV–1. Trans R Soc Trop Med Hyg 1996; 90:383.

Alvar J, Canavate C, Gutíérrez–Solar R, Jiménez M, Laguna F, López–Vélez R, Molina R, Moreno J. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Microbiol Rev 1997; 10: 298–318.

Silva Júnior GB, Libório AB, Mota RMS, Abreu KLS, Silva AEB, Araújo SMHA, Daher EF. Acute kidney injury in AIDS: frequency, RIFLE classification and outcome. Braz J Med Biol Res 2010; 43: 1102–1108.

Daher EEF, Evangelista LF, Silva Junior GB, Lima RSA, Aragão EB, Arruda GAJC, et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (Kala–azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis 2008; 12:329–332.

Pisani R, Wille KM, Tolwani AJ. The epidemiology of severe acute kidney injury. From BEST to PICARD, in Acute Kidney Injury: New Concepts. Nephron Clin Pract 2008; 109: 188–191.

Person D; Sousa AQ. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996; 22: 1–13.

Patorino AC, Jacob CMA, Oselja GW, Carneiro–Sampaio MMS. Visceral leishmaniasis: Clin Lab Aspects J Ped 2002; 78: 120–127.

Pedrosa CM; Rocha EMM. Clinical and epidemiological aspects of visceral leishmaniasis in children under 15 years coming from Alagoas, Brazil. Rev Soc Bras Med Trop 1994; 37: 300–304.

Xavier–Gomes LM, Costa WB, Prado PPF, Oliveira–Campos M, Leite MT. Clinical and epidemiological characteristics of visceral leishmaniasis in children hospitalized at a reference university hospital in the North of Minas Gerais, Brazil. Rev Bras Epidemiol 2009; 12: 1–6.

Albuquerque PLMM, Silva Junior GB, Freire CCP, Oliveira SBC, Almeida DM, Silva HF, et al. Urbanization of visceral leishmaniasis (Kala–azar) in Fortaleza, Ceara, Brazil. Rev Panam Salud Publica 2009; 26: 330–333.

Daher EF, Fonseca PP, Gerhard ES, Silva Leitão TMJ, Silva Júnior GB. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol 2009; 95: 652–655.

Gallardo JA, Pineda JA, Macias J, Torrontera R, Lissen E. Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in patients with HIV–1. Trans R Soc Trop Med Hyg 1996; 90:383.

Alvar J, Canavate C, Gutíérrez–Solar R, Jiménez M, Laguna F, López–Vélez R, Molina R, Moreno J. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Microbiol Rev 1997; 10: 298–318.

Silva Júnior GB, Libório AB, Mota RMS, Abreu KLS, Silva AEB, Araújo SMHA, Daher EF. Acute kidney injury in AIDS: frequency, RIFLE classification and outcome. Braz J Med Biol Res 2010; 43: 1102–1108.

Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV–infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2003; 40: 1559–1585.

Franceschini N, Napravnik S, Eron JJ Jr, Szczecz LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV–infected patients. Kidney Int 2005; 67: 1526–1531.

Wyatt CM, Klotman PE. HIV–associated nephropathy in the era of antiretroviral therapy. Am J Med 2007; 120: 488–492.

Silva Júnior GB, Daher EF. Renal Involvement in Leprosy: Retrospective Analysis of 461 Cases in Brazil. Braz J Infect Dis 2006; 10(2):107–112.

Nakayama EE, Ura S, Negro RF. Lesões renais em Hanseníase. J Bras Nefrol 1995; 17: 148–157.

Nakayama EE, Ura S, Fleury RN, Soares V. Renal lesions in Leprosy: a retrospective study of 199 autopsies. Am J Kidney Dis 2001; 38: 26–30.

Ahsan N, Wheeler DE, Palmer BF. Leprosy–associated renal disease: case report and review of the literature. J Am Soc Nephrol 1995; 5: 1546–1552.

Chugh KS, Kaur S, Kumar B. Renal lesions in leprosy amongst north India patients. Postgrad Med J 1983; 59: 707–711.

Chugh KS, Sakhjuva V. Renal lesions in Leprosy. J Assoc Physicians India 1991; 39: 163–164.

Date A, Johny KV. Glomerular subepithelial deposits in lepromatous leprosy–microscopic study. Am J Trop Med Hyg 1973; 24: 853–866.

Jain PK, Kumar S, Govil DC. Renal changes in Leprosy and its reactions. In: Abstracts of the X International Congress of Nephrology. London; 1987, p.69.

Nakayama EE, Ura S, Fleury RN, Soares V. Renal lesions in Leprosy: a retrospective study of 199 autopsies. Am J Kidney Dis 2001; 38: 26–30.

Peter KS, Vijayakumar T, Vasudevan DM. Renal involvement in Leprosy. Lepr India 1981; 53: 163–178.

Weiner ID, Northcutt AD. Leprosy and glomerulonephritis: Case report and review of literature. Am J Kidney Dis 1989; 13: 424–429.

Date A, Thomas A, Mathal R, Johny KV. Glomerular pathology in Leprosy and electron microscopic study. Am J Trop Med Hyg 1977; 26: 266–272.

Mittal MM, Agarwal SC, Maheshwari HB, Kumar S. Renal lesions in Leprosy. Arch Pathol 1972; 93: 8–12.

Klizio AM, Ramos–Caro FA. Visceral leprosy. Int J Dermatol 2000; 39: 641–658.

Kirsztajn GM, Pereira AB. Comprometimento renal na Hanseníase. In: Cruz J, Barros RT (eds.) Atualidades em Nefrologia 4. São Paulo: Sarvier, 1996.

Schutterwirth JS, Ross SH. Secondary amyloidosis in Leprosy. Ann Intern Med 1956; 45: 23–38.

Singhal PC, Chugh KS, Kaur S, Malik AK. Acute renal failure in leprosy. Int J Lepr 1977; 45: 171–174.

Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 35: 59–69.

Werneck GL, Batista MS, Gomes JR, Costa CH. Prognostic factors from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31: 174–177.